Amrein R, Hetzel W, Stabl M, Schmid-Burgk W
Department of Clinical Research, Neuropsychiatry, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Int Clin Psychopharmacol. 1993 Jan;7(3-4):123-32. doi: 10.1097/00004850-199300730-00001.
Moclobemide, a specific reversible inhibitor of monoamine oxidase that shows a preference for the A isoenzyme, has been developed as a new antidepressive agent. Unlike earlier generation monoamine oxidase inhibitors, moclobemide is devoid of any clinically significant tyramine interaction, thus making dietary restrictions during therapy unnecessary. In comparative trials, moclobemide has been found to be superior to placebo and similar to imipramine, clomipramine, and amitriptyline in clinical efficacy. Long-term trials involving moclobemide therapy for up to one year have indicated that antidepressant efficacy can be maintained for this period. Tolerance is good and is significantly better than for tricyclic antidepressants. In addition, unlike the tricyclic antidepressants, overdoses of moclobemide do not appear to be life-threatening.
吗氯贝胺是一种对单胺氧化酶具有特异性的可逆抑制剂，对A型同工酶表现出偏好，已被开发为一种新型抗抑郁药。与早期的单胺氧化酶抑制剂不同，吗氯贝胺没有任何具有临床意义的酪胺相互作用，因此在治疗期间无需进行饮食限制。在比较试验中，已发现吗氯贝胺在临床疗效上优于安慰剂，且与丙咪嗪、氯米帕明和阿米替林相似。涉及长达一年吗氯贝胺治疗的长期试验表明，在此期间抗抑郁疗效可以维持。耐受性良好，明显优于三环类抗抑郁药。此外，与三环类抗抑郁药不同，过量服用吗氯贝胺似乎不会危及生命。
